Braidwell LP Sells 781,587 Shares of MBX Biosciences, Inc. $MBX

Braidwell LP lowered its stake in MBX Biosciences, Inc. (NASDAQ:MBX) by 52.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 710,880 shares of the company’s stock after selling 781,587 shares during the period. MBX Biosciences accounts for 1.5% of Braidwell LP’s portfolio, making the stock its 27th largest position. Braidwell LP owned 1.48% of MBX Biosciences worth $39,241,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of the stock. State of Wyoming bought a new position in MBX Biosciences in the 2nd quarter valued at $58,000. Russell Investments Group Ltd. raised its position in shares of MBX Biosciences by 4,131.4% during the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock worth $26,000 after acquiring an additional 1,446 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of MBX Biosciences by 59.6% during the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock valued at $49,000 after acquiring an additional 572 shares during the period. Strs Ohio lifted its stake in shares of MBX Biosciences by 128.6% during the first quarter. Strs Ohio now owns 1,600 shares of the company’s stock valued at $48,000 after acquiring an additional 900 shares during the period. Finally, California State Teachers Retirement System boosted its holdings in MBX Biosciences by 64.7% in the fourth quarter. California State Teachers Retirement System now owns 1,754 shares of the company’s stock valued at $55,000 after acquiring an additional 689 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts recently commented on MBX shares. Barclays reiterated an “overweight” rating and issued a $88.00 price objective on shares of MBX Biosciences in a research report on Friday, August 7th. Citizens Jmp raised their target price on shares of MBX Biosciences from $76.00 to $86.00 and gave the company a “market outperform” rating in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MBX Biosciences in a research report on Friday, July 17th. Mizuho boosted their price target on shares of MBX Biosciences from $57.00 to $91.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Finally, JPMorgan Chase & Co. started coverage on shares of MBX Biosciences in a report on Friday, August 21st. They issued an “overweight” rating and a $88.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $77.00.

MBX Biosciences Price Performance

Shares of MBX stock opened at $60.89 on Thursday. The stock has a market cap of $2.93 billion, a PE ratio of -25.27 and a beta of 0.04. The stock has a 50-day moving average of $62.69 and a 200-day moving average of $43.55. MBX Biosciences, Inc. has a one year low of $9.63 and a one year high of $72.64.

MBX Biosciences (NASDAQ:MBX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.10). As a group, research analysts anticipate that MBX Biosciences, Inc. will post -3.11 earnings per share for the current year.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.